Rohto Pharmaceutical Co.,Ltd.
4527.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥308,625 | ¥270,840 | ¥238,664 | ¥199,646 |
| % Growth | 14% | 13.5% | 19.5% | – |
| Cost of Goods Sold | ¥139,244 | ¥113,554 | ¥101,243 | ¥83,157 |
| Gross Profit | ¥169,381 | ¥157,286 | ¥137,421 | ¥116,489 |
| % Margin | 54.9% | 58.1% | 57.6% | 58.3% |
| R&D Expenses | ¥14,912 | ¥11,796 | ¥11,065 | ¥8,740 |
| G&A Expenses | ¥58,498 | ¥47,087 | ¥44,012 | ¥39,346 |
| SG&A Expenses | ¥116,004 | ¥101,306 | ¥90,479 | ¥77,460 |
| Sales & Mktg Exp. | ¥57,506 | ¥54,219 | ¥46,467 | ¥38,114 |
| Other Operating Expenses | ¥0 | ¥4,136 | ¥1,913 | ¥935 |
| Operating Expenses | ¥130,916 | ¥117,238 | ¥103,457 | ¥87,135 |
| Operating Income | ¥38,465 | ¥40,048 | ¥33,959 | ¥29,349 |
| % Margin | 12.5% | 14.8% | 14.2% | 14.7% |
| Other Income/Exp. Net | ¥3,392 | ¥1,470 | ¥331 | -¥1,397 |
| Pre-Tax Income | ¥42,331 | ¥41,518 | ¥34,290 | ¥27,953 |
| Tax Expense | ¥11,379 | ¥10,123 | ¥7,860 | ¥6,686 |
| Net Income | ¥31,005 | ¥30,936 | ¥26,377 | ¥21,127 |
| % Margin | 10% | 11.4% | 11.1% | 10.6% |
| EPS | 136.11 | 135.6 | 115.62 | 92.61 |
| % Growth | 0.4% | 17.3% | 24.8% | – |
| EPS Diluted | 135.46 | 135.21 | 115.29 | 92.34 |
| Weighted Avg Shares Out | 228 | 228 | 228 | 228 |
| Weighted Avg Shares Out Dil | 229 | 229 | 229 | 229 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥1,223 | ¥1,523 | ¥962 | ¥368 |
| Interest Expense | ¥949 | ¥196 | ¥247 | ¥248 |
| Depreciation & Amortization | ¥13,143 | ¥8,687 | ¥7,801 | ¥7,689 |
| EBITDA | ¥56,424 | ¥50,403 | ¥42,338 | ¥35,810 |
| % Margin | 18.3% | 18.6% | 17.7% | 17.9% |